To determine the need and extent of mandible resection, it is essential to understand the pathway by which oral cancers invade the mandible .
-
Primary carcinomas of the lip, buccal mucosa, tongue, and floor of the mouth extend along the surface mucosa and the submucosal soft tissues to approach the attached labial, buccal, or lingual gingiva.
-
From this point, the tumor does not extend directly through intact periosteum and cortical bone toward the cancellous part of the mandible because the periosteum acts as a significant protective barrier .
-
Instead, the tumor advances from the attached gingiva toward the alveolus.
-
In patients with teeth, the tumor extends through the dental socket into the cancellous part of the bone and invades the mandible in that fashion (Figure).

- Tumor invasion of the dentate mandible occurs through the dental socket to the cancellous bone and then to the alveolar canal.
In edentulous patients, the tumor extends up to the alveolar process and then infiltrates the dental pores in the alveolar ridge and extends to the cancellous part of the mandible (Figure)

- Tumor invasion of the edentulous mandible occurs through the dental pores on the alveolar process to the cancellous bone and then to the alveolar canal.
-
Thus even in patients with early invasion of the mandible, a marginal mandibulectomy is feasible because the cortical part of the mandible inferior to the roots of the teeth remains uninvolved and can be safely spared.
-
In edentulous patients, however, the feasibility of marginal mandibulectomy depends on the vertical height of the body of the mandible .
-
With aging, the alveolar process recedes and the mandibular canal comes closer to the surface of the alveolar process.
-
As shown in the Figure, the resorption of the alveolar process eventually leads to a “pipestem” mandible in elderly patients.

- Vertical height and location of the alveolar canal in dentate and edentulous mandibles.
The ability to perform a satisfactory marginal mandibulectomy in such patients is almost impossible because the probability of iatrogenic fracture or postsurgical spontaneous fracture of the remaining portion of the mandible is very high.
-
Similarly, in patients who have received previous radiotherapy, a marginal mandibulectomy should be performed with extreme caution.
-
The probability of pathological fracture at the site of the marginal mandibulectomy in such patients is very high.
When the tumor extends to involve the cancellous part of the mandible, a segmental mandibulectomy must be performed.
-
A segmental mandibulectomy also may be required in patients with massive primary tumors with significant soft tissue disease in the proximity of the mandible.

Rodrigo Arrangoiz MS, MD, FACS a head and neck surgeon and a member of Sociedad Quirúrgica S.C at the America British Cowdray Medical Center.
He is first author on some publications on oral cavity cancer:
- Oral Tongue Cancer: Literature Review and Current Management
- Understand Cancer: Research and Treatment Oral Cavity Cancer: Literature Review and Current Management.
Training:
• General surgery:
• Michigan State University:
• 2004 al 2010

• Surgical Oncology / Head and Neck Surgery / Endocrine Surgery:
• Fox Chase Cancer Center (Filadelfia):
• 2010 al 2012

• Masters in Science (Clinical research for health professionals):
• Drexel University (Filadelfia):
• 2010 al 2012

• Surgical Oncology / Head and Neck Surgery / Endocrine Surgery:
• IFHNOS / Memorial Sloan Kettering Cancer Center:
• 2014 al 2016

Published by Rodrigo Arrangoiz MS, MD, FACS, FSSO
My name is Rodrigo Arrangoiz I am a breast surgeon/ thyroid surgeon / parathyroid surgeon / head and neck surgeon / surgical oncologist that works at Center for Advanced Surgical Oncology in Miami, Florida.
I was trained as a surgeon at Michigan State University from (2005 to 2010) where I was a chief resident in 2010. My surgical oncology and head and neck training was performed at the Fox Chase Cancer Center in Philadelphia from 2010 to 2012. At the same time I underwent a masters in science (Clinical research for health professionals) at the University of Drexel. Through the International Federation of Head and Neck Societies / Memorial Sloan Kettering Cancer Center I performed a two year head and neck surgery and oncology / endocrine fellowship that ended in 2016.
Mi nombre es Rodrigo Arrangoiz, soy cirujano oncólogo / cirujano de tumores de cabeza y cuello / cirujano endocrino que trabaja Center for Advanced Surgical Oncology en Miami, Florida.
Fui entrenado como cirujano en Michigan State University (2005 a 2010 ) donde fui jefe de residentes en 2010. Mi formación en oncología quirúrgica y e n tumores de cabeza y cuello se realizó en el Fox Chase Cancer Center en Filadelfia de 2010 a 2012. Al mismo tiempo, me sometí a una maestría en ciencias (investigación clínica para profesionales de la salud) en la Universidad de Drexel. A través de la Federación Internacional de Sociedades de Cabeza y Cuello / Memorial Sloan Kettering Cancer Center realicé una sub especialidad en cirugía de cabeza y cuello / cirugia endocrina de dos años que terminó en 2016.
View all posts by Rodrigo Arrangoiz MS, MD, FACS, FSSO